Mark A. Goldsmith - 16 Sep 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: RVMD
Reported as of: 16 Sep 2026
Net transaction value: -$2,786,938
SEC form: 4
Accepted by SEC: 18 Sep 2026, 18:02:05 UTC
Prior SEC filing: 25 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as attorney-in-fact for Mark A. Goldsmith, M.D., Ph.D.

Key filing fact

Mark A. Goldsmith filed Form 4 for Revolution Medicines, Inc. (RVMD) on 18 Sep 2026.

Key facts

This page summarizes Mark A. Goldsmith's Form 4 filing for Revolution Medicines, Inc. (RVMD).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Sep 2026, 18:02.

Change

Previous filing in this sequence was filed on 25 Aug 2026.
Current net transaction value: -$2,786,938.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001246842 Primary reporting owner

GOLDSMITH MARK A

Relationship: President and Chief Executive Officer, Director
Address: REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as attorney-in-fact for Mark A. Goldsmith, M.D., Ph.D.
Signature date: 18 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $41,537
Shares: -213
Change %: -0.08%
Price: $195.01
Shares after: 267,117
Date: 16 Sep 2026
Ownership: Direct
Footnotes: F1, F2

RVMD transaction

Common Stock

Sale

Transaction value: $2,745,402
Shares: -13,775
Change %: -5.2%
Price: $199.30
Shares after: 253,342
Date: 16 Sep 2026
Ownership: Direct
Footnotes: F1, F3

RVMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 594,060
Date: 16 Sep 2026
Ownership: Trust
Footnotes: F4

RVMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 61,424
Date: 16 Sep 2026
Ownership: Trust
Footnotes: F5

RVMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 61,424
Date: 16 Sep 2026
Ownership: Trust
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

Footnote F2

The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

Includes 157,588 restricted stock units.

Footnote F4

Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Footnote F5

Held by Jonathan Goldsmith Revocable Trust.

Footnote F6

Held by Rebecca Goldsmith Revocable Trust.

SEC remarks

President and Chief Executive Officer